250 related articles for article (PubMed ID: 26338826)
21. EGFR gene mutation in gastrointestinal stromal tumours.
Shi SS; Wu N; He Y; Wei X; Xia QY; Wang X; Ye SB; Li R; Rao Q; Zhou XJ
Histopathology; 2017 Oct; 71(4):553-561. PubMed ID: 28485054
[TBL] [Abstract][Full Text] [Related]
22. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
Wei ZW; Wu J; Huang WB; Li J; Lu XF; Yuan YJ; Xiong WJ; Zhang XH; Wang W; He YL; Zhang CH
EBioMedicine; 2020 Jul; 57():102850. PubMed ID: 32574962
[TBL] [Abstract][Full Text] [Related]
23. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
24. SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion.
Chen Z; Raghoonundun C; Chen W; Zhang Y; Tang W; Fan X; Shi X
Biochem Biophys Res Commun; 2018 Apr; 498(3):579-585. PubMed ID: 29522714
[TBL] [Abstract][Full Text] [Related]
25. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
26. Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors.
Cannella R; Tabone E; Porrello G; Cappello G; Gozzo C; Incorvaia L; Grignani G; Merlini A; D'Ambrosio L; Badalamenti G; Regge D; Bartolotta TV
Eur Radiol; 2021 Nov; 31(11):8554-8564. PubMed ID: 33881567
[TBL] [Abstract][Full Text] [Related]
27. Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.
Belinsky MG; Rink L; Cai KQ; Capuzzi SJ; Hoang Y; Chien J; Godwin AK; von Mehren M
BMC Cancer; 2015 Nov; 15():887. PubMed ID: 26555092
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of pleomorphism in gastrointestinal stromal tumours.
Isidro RA; Hornick JL
Histopathology; 2022 Feb; 80(3):598-603. PubMed ID: 34562043
[TBL] [Abstract][Full Text] [Related]
29. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
31. Pathological characteristics of gastrointestinal stromal tumours with PDGFRA mutations.
Kwon JE; Kang HJ; Kim SH; Lee YC; Hyung WJ; Noh SH; Kim NK; Kim H
Pathology; 2009; 41(6):544-54. PubMed ID: 19900103
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
33. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
[TBL] [Abstract][Full Text] [Related]
34. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.
Parker H; Rose-Zerilli MJ; Larrayoz M; Clifford R; Edelmann J; Blakemore S; Gibson J; Wang J; Ljungström V; Wojdacz TK; Chaplin T; Roghanian A; Davis Z; Parker A; Tausch E; Ntoufa S; Ramos S; Robbe P; Alsolami R; Steele AJ; Packham G; Rodríguez-Vicente AE; Brown L; McNicholl F; Forconi F; Pettitt A; Hillmen P; Dyer M; Cragg MS; Chelala C; Oakes CC; Rosenquist R; Stamatopoulos K; Stilgenbauer S; Knight S; Schuh A; Oscier DG; Strefford JC
Leukemia; 2016 Nov; 30(11):2179-2186. PubMed ID: 27282254
[TBL] [Abstract][Full Text] [Related]
35. Molecular cytology genotyping of primary and metastatic GI stromal tumors by using a custom two-gene targeted next-generation sequencing panel with therapeutic intent.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Gastrointest Endosc; 2016 Dec; 84(6):950-958.e3. PubMed ID: 27118626
[TBL] [Abstract][Full Text] [Related]
36. Comparative clinical features and short-term outcomes of gastric and small intestinal gastrointestinal stromal tumours: a retrospective study.
Yang Z; Wang F; Liu S; Guan W
Sci Rep; 2019 Jul; 9(1):10033. PubMed ID: 31296939
[TBL] [Abstract][Full Text] [Related]
37. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
[TBL] [Abstract][Full Text] [Related]
39.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
40. Genomic aberrations in cell cycle genes predict progression of
Heinrich MC; Patterson J; Beadling C; Wang Y; Debiec-Rychter M; Dewaele B; Corless CL; Duensing A; Raut CP; Rubin B; Ordog T; van de Rijn M; Call J; Mühlenberg T; Fletcher JA; Bauer S
Clin Sarcoma Res; 2019; 9():3. PubMed ID: 30867899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
